サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1518846

膣用抗真菌薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2032年

Vaginal Antifungals Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2032

出版日
ページ情報
英文 250 Pages
納期
2～5営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=148.90円
膣用抗真菌薬市場：世界の産業分析、規模、シェア、成長、動向、予測、2024年～2032年
出版日: 2024年07月17日
発行: Persistence Market Research
ページ情報: 英文 250 Pages
納期: 2～5営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

Persistence Market Research社はこのほど、世界の膣用抗真菌薬市場に関する包括的なレポートを発表しました。本レポートでは、市場促進要因・動向・機会・課題を含む重要な市場力学を徹底的に評価し、市場構造に関する詳細な洞察を提供しています。

主要な洞察

  • 膣用抗真菌薬の市場規模（2024年）：11億米ドル
  • 市場予測値（2032年）：14億米ドル
  • 世界市場成長率（CAGR 2024年～2032年）：2.7%

膣用抗真菌薬市場：調査範囲

膣用抗真菌薬は、膣領域を侵すカンジダ症を含む真菌感染症の治療に不可欠です。これらの薬剤はクリーム、座薬、錠剤、軟膏など様々な形態があり、患者のニーズや嗜好に合わせて調整されます。膣用抗真菌薬市場は、薬局、病院、診療所、オンライン小売に対応し、症状を緩和し、感染症を効果的に除去するための幅広い治療オプションを提供しています。市場成長の原動力は、女性の健康問題に対する意識の高まり、真菌感染症の有病率の上昇、有効性と患者の快適性を高める抗真菌製剤の進歩です。

市場促進要因：

世界の膣用抗真菌薬市場は、膣真菌感染症を迅速かつ効果的に治療することの重要性に対する意識の高まりなど、いくつかの重要な要因によって推進されています。特に湿度が高く、衛生習慣の悪い地域でのカンジダ症罹患率の上昇が、市場拡大をさらに後押ししています。新規製剤やドラッグデリバリーシステムの開発などの技術の進歩は、治療結果の改善と副作用の軽減をもたらし、市場の成長を促進します。さらに、一般用医薬品（OTC）抗真菌剤の利用可能性の増加やeコマースプラットフォームの拡大は、市場企業がより幅広い消費者層にリーチするための新たな道を作り出しています。

市場抑制要因：

有望な成長が見込まれる一方で、膣用抗真菌薬市場は規制遵守、薬剤耐性、抗真菌薬の長期使用に伴う副作用に関する課題に直面しています。抗真菌薬の製造、販売、使用に関する厳しい規制は、メーカーやヘルスケアプロバイダーにコンプライアンスの負担を課し、市場参入の障壁や運営コストに影響を与えます。さらに、薬剤耐性真菌の出現や抗真菌治療の潜在的な副作用は、特に医療予算に制約のある新興国において、市場浸透の課題となっています。このような規制や臨床上の障壁に対処するには、安全で効果的な抗真菌薬へのアクセスを促進するために、業界の利害関係者と政策立案者が協力する必要があります。

市場機会：

膣用抗真菌薬市場は、技術革新、人口動向、進化するヘルスケア提供モデルによって大きな成長機会がもたらされます。遠隔医療プラットフォームやモバイルヘルスアプリなどのデジタルヘルス技術の統合は、患者の抗真菌治療へのアクセスを向上させ、治療のアドヒアランスとアウトカムを改善します。さらに、再発性感染症の予防と治療における抗真菌薬の適用拡大が、市場の範囲を広げ、技術革新を刺激しています。戦略的パートナーシップ、研究開発への投資、ユーザーフレンドリーで費用対効果の高い抗真菌ソリューションのイントロダクションは、新たなビジネスチャンスを生かし、ダイナミックな膣用抗真菌薬市場においてリーダーシップを維持するために不可欠です。

本レポートで扱う主な質問

  • 世界の膣用抗真菌薬市場の成長を促進する主な要因は何か？
  • 様々なヘルスケアシーンで抗真菌剤の採用を促進している製品タイプと用途は何か？
  • 技術の進歩は膣用抗真菌薬市場の競合情勢をどのように変えているのか？
  • 膣用抗真菌薬市場に貢献している主要企業はどこで、また市場の関連性を維持するためにどのような戦略を採用しているか？
  • 世界の膣用抗真菌薬市場における新たな動向と将来性は？

目次

第1章 エグゼクティブサマリー

第2章 市場概要

  • 市場範囲/ 分類
  • 市場の定義/ 範囲/ 制限
  • 包含と除外

第3章 主要な市場動向

  • 市場に影響を与える主な動向
  • 主要なイノベーション/開発動向

第4章 主要な成功要因

  • 主要メーカーによるプロモーション戦略
  • 主な規制
  • 払い戻しシナリオ
  • パイプライン分析
  • バリューチェーン分析
  • PESTEL分析
  • ポーターの分析

第5章 市場背景

  • マクロ経済要因
  • 予測要因 - 関連性と影響
  • 市場力学

第6章 COVID-19危機分析

  • COVID-19と影響分析
    • 薬剤別
    • 投与経路別
    • 流通チャネル別
    • 国別
  • 2024年の市場シナリオ

第7章 世界の膣用抗真菌薬市場の需要分析

  • 過去の市場金額分析、2019年～2023年
  • 現在および将来の市場金額予測、2024年～2032年
    • 前年比成長動向分析
    • 絶対額の機会

第8章 世界の膣用抗真菌薬市場分析：薬剤別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：薬剤別、2019年～2023年
  • 現在および将来の市場規模分析と予測：薬剤別、2024年～2032年
    • フルコナゾール
    • ナイスタチン
    • フルシトシン
    • クロトリマゾール
    • ケトコナゾール
    • テルビナフィン
    • その他
  • 薬剤別の市場の魅力分析

第9章 世界の膣用抗真菌薬市場分析：投与経路別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：投与経路別、2019年～2023年
  • 現在および将来の市場規模分析と予測：投与経路別、2024年～2032年
    • 経口
    • 局所
  • 投与経路別の市場の魅力分析

第10章 世界の膣用抗真菌薬市場分析：流通チャネル別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：流通チャネル別、2019～2023年
  • 現在および将来の市場規模分析と予測：流通チャネル別、2024～2032年
    • 病院薬局
    • 小売薬局
    • オンライン薬局
  • 流通チャネル別の市場の魅力分析

第11章 世界の膣用抗真菌薬市場分析：地域別

  • イントロダクション/主な調査結果
  • 過去の市場規模分析：地域別、2019年～2023年
  • 現在および将来の市場規模分析と予測：地域別、2024年～2032年
    • 北米
    • ラテンアメリカ
    • 欧州
    • 東アジア
    • 南アジア
    • オセアニア
    • 中東・アフリカ
  • 地域別の市場の魅力分析

第12章 北米の膣用抗真菌薬市場分析

第13章 ラテンアメリカの膣用抗真菌薬市場分析

第14章 欧州の膣用抗真菌薬市場分析

第15章 東アジアの膣用抗真菌薬市場分析

第16章 南アジアの膣用抗真菌薬市場分析

第17章 オセアニアの膣用抗真菌薬市場

第18章 中東・アフリカの膣用抗真菌薬市場分析

第19章 市場構造分析

  • 企業階層別の市場分析
  • 市場集中
  • 主要企業の市場シェア分析
  • 市場プレゼンス分析

第20章 競合分析

  • 競合ダッシュボード
  • 競合ベンチマーク
  • 競合の詳細
    • Pfizer Inc.
    • Bausch Health Companies Inc
    • ANI Pharmaceuticals, Inc.
    • Hikma Pharmaceuticals Plc
    • Lupin Limited
    • Mycovia Pharmaceuticals, Inc.
    • Glenmark Pharmaceuticals Limited
    • Unique Pharmaceuticals
    • PEPTONIC medical AB
    • Aurobindo Pharma Limited
    • Dr. Reddy's Laboratories
    • SCYNEXIS, Inc.
    • Basilea Pharmaceutica Ltd.
    • Astellas Pharma Inc.
    • Grupo Ferrer Internacional, SA
    • Pacgen Life Science Corporation
    • NovaDigm Therapeutics, Inc.
    • Cidara Therapeutics, Inc.
    • Amplyx Pharmaceuticals Inc.

第21章 前提と頭字語

第22章 調査手法

目次
Product Code: PMRREP33292

Persistence Market Research has recently released a comprehensive report on the worldwide market for vaginal antifungals. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

  • Vaginal Antifungals Market Size (2024E): USD 1.1 Billion
  • Projected Market Value (2032F): USD 1.4 Billion
  • Global Market Growth Rate (CAGR 2024 to 2032): 2.7%

Vaginal Antifungals Market - Report Scope:

Vaginal antifungals are essential in the treatment of fungal infections, including candidiasis, that affect the vaginal area. These medications come in various forms, such as creams, suppositories, tablets, and ointments, tailored to different patient needs and preferences. The vaginal antifungals market caters to pharmacies, hospitals, clinics, and online retail, offering a range of treatment options to alleviate symptoms and eliminate infections effectively. Market growth is driven by increasing awareness of women's health issues, rising prevalence of fungal infections, and advancements in antifungal formulations enhancing efficacy and patient comfort.

Market Growth Drivers:

The global vaginal antifungals market is propelled by several key factors, including growing awareness about the importance of treating vaginal fungal infections promptly and effectively. The rising incidence of candidiasis, particularly in regions with high humidity and poor hygiene practices, further drives market expansion. Technological advancements, such as the development of novel drug formulations and delivery systems, offer improved treatment outcomes and reduced side effects, fostering market growth. Moreover, the increasing availability of over-the-counter (OTC) antifungal products and the expansion of e-commerce platforms create new avenues for market players to reach a broader consumer base.

Market Restraints:

Despite promising growth prospects, the vaginal antifungals market faces challenges related to regulatory compliance, drug resistance, and side effects associated with prolonged antifungal use. Stringent regulations governing the manufacturing, marketing, and use of antifungal medications impose compliance burdens on manufacturers and healthcare providers, affecting market entry barriers and operational costs. Furthermore, the emergence of drug-resistant fungal strains and the potential side effects of antifungal treatments pose challenges for market penetration, particularly in emerging economies with constrained healthcare budgets. Addressing these regulatory and clinical barriers requires collaboration between industry stakeholders and policymakers to promote access to safe and effective antifungal solutions.

Market Opportunities:

The vaginal antifungals market presents significant growth opportunities driven by technological innovations, demographic trends, and evolving healthcare delivery models. The integration of digital health technologies, such as telemedicine platforms and mobile health apps, enhances patient access to antifungal treatments and improves treatment adherence and outcomes. Furthermore, the expanding application of antifungals in preventing and treating recurrent infections broadens the market scope and stimulates innovation. Strategic partnerships, investment in research and development, and the introduction of user-friendly, cost-effective antifungal solutions are essential to capitalize on emerging opportunities and sustain market leadership in the dynamic vaginal antifungals landscape.

Key Questions Answered in the Report:

  • What are the primary factors driving the growth of the vaginal antifungals market globally?
  • Which product types and applications are driving antifungal adoption across different healthcare settings?
  • How are technological advancements reshaping the competitive landscape of the vaginal antifungals market?
  • Who are the key players contributing to the vaginal antifungals market, and what strategies are they employing to maintain market relevance?
  • What are the emerging trends and future prospects in the global vaginal antifungals market?

Competitive Intelligence and Business Strategy:

Leading players in the global vaginal antifungals market, including Bayer AG, Pfizer Inc., and Johnson & Johnson, focus on innovation, product differentiation, and strategic partnerships to gain a competitive edge. These companies invest in R&D to develop advanced antifungal formulations, including combination therapies and extended-release formulations, catering to diverse patient needs and clinical requirements. Collaborations with healthcare providers, pharmacies, and regulatory agencies facilitate market access and promote technology adoption. Moreover, emphasis on clinical research, evidence-based practice, and patient education fosters market growth and enhances patient outcomes in the rapidly evolving antifungals landscape.

Key Companies Profiled:

  • Pfizer Inc.
  • Bausch Health Companies Inc
  • ANI Pharmaceuticals, Inc.
  • Hikma Pharmaceuticals Plc
  • Lupin Limited
  • Mycovia Pharmaceuticals, Inc.
  • Glenmark Pharmaceuticals Limited
  • Unique Pharmaceuticals
  • PEPTONIC Medical AB
  • Aurobindo Pharma Limited
  • Dr. Reddy's Laboratories
  • SCYNEXIS, Inc.
  • Basilea Pharmaceutica Ltd.
  • Astellas Pharma Inc.
  • Grupo Ferrer Internacional, S.A.
  • Pacgen Life Science Corporation
  • NovaDigm Therapeutics, Inc.
  • Cidara Therapeutics, Inc.
  • Amplyx Pharmaceuticals Inc.

Vaginal Antifungals Industry Research Segments

By Drug:

  • Fluconazole
  • Nystatin
  • Flucytosine
  • Clotrimazole
  • Ketoconazole
  • Terbinafine

By Route of Administration:

  • Oral
  • Topical

By Distribution Channel:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Region:

  • North America
  • Latin America
  • Europe
  • South Asia
  • East Asia
  • Oceania
  • Middle East & Africa (MEA)

Table of Contents

1. Executive Summary

  • 1.1. Global Market Outlook
  • 1.2. Demand Side Trends
  • 1.3. Supply Side Trends
  • 1.4. Analysis and Recommendations

2. Market Overview

  • 2.1. Market Coverage / Taxonomy
  • 2.2. Market Definition / Scope / Limitations
  • 2.3. Inclusions and Exclusions

3. Key Market Trends

  • 3.1. Key Trends Impacting the Market
  • 3.2. Key Innovation / Development Trends

4. Key Success Factors

  • 4.1. Promotional Strategies, By Key Manufacturers
  • 4.2. Key Regulations
  • 4.3. Reimbursement Scenario
  • 4.4. Pipeline Analysis
  • 4.5. Value Chain Analysis
  • 4.6. PESTEL Analysis
  • 4.7. Porter's Analysis

5. Market Background

  • 5.1. Macro-Economic Factors
    • 5.1.1. Global GDP Growth Outlook
    • 5.1.2. Global Healthcare Expenditure Outlook
    • 5.1.3. Global Antifungal Drugs Market Outlook
  • 5.2. Forecast Factors - Relevance & Impact
    • 5.2.1. Impact of the COVID-19 Pandemic
    • 5.2.2. Increasing Product Launch Activities
    • 5.2.3. Prevalence of Vaginal Fungal Infections in HRT Patients
    • 5.2.4. High Rates of Vulvovaginal Candidiasis
    • 5.2.5. Impact on Quality-of-Life
    • 5.2.6. Increasing Number of People with Predisposing Conditions Such as Diabetes Treated with SGLT2 Inhibitors
    • 5.2.7. Growing Problems of Azole Resistance
    • 5.2.8. Toxicity of Antifungal Drugs
  • 5.3. Market Dynamics
    • 5.3.1. Drivers
    • 5.3.2. Restraints
    • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

  • 6.1. COVID-19 and Impact Analysis
    • 6.1.1. By Drug
    • 6.1.2. By Route of Administration
    • 6.1.3. By Distribution Channel
    • 6.1.4. By Country
  • 6.2. 2024 Market Scenario

7. Global Vaginal Antifungals Market Demand (in Value or Size in US$ Bn) Analysis 2019-2023 and Forecast, 2024-2032

  • 7.1. Historical Market Value (US$ Bn) Analysis, 2019-2023
  • 7.2. Current and Future Market Value (US$ Bn) Projections, 2024-2032
    • 7.2.1. Y-o-Y Growth Trend Analysis
    • 7.2.2. Absolute $ Opportunity Analysis

8. Global Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032, By Drug

  • 8.1. Introduction / Key Findings
  • 8.2. Historical Market Size (US$ Bn) Analysis By Drug, 2019-2023
  • 8.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Drug, 2024-2032
    • 8.3.1. Fluconazole
    • 8.3.2. Nystatin
    • 8.3.3. Flucytosine
    • 8.3.4. Clotrimazole
    • 8.3.5. Ketoconazole
    • 8.3.6. Terbinafine
    • 8.3.7. Others
  • 8.4. Market Attractiveness Analysis By Drug

9. Global Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032, By Route of Administration

  • 9.1. Introduction / Key Findings
  • 9.2. Historical Market Size (US$ Bn) Analysis By Route of Administration, 2019-2023
  • 9.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Route of Administration, 2024-2032
    • 9.3.1. Oral
    • 9.3.2. Topical
  • 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032, By Distribution Channel

  • 10.1. Introduction / Key Findings
  • 10.2. Historical Market Size (US$ Bn) Analysis By Distribution Channel, 2019-2023
  • 10.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Distribution Channel, 2024-2032
    • 10.3.1. Hospital Pharmacies
    • 10.3.2. Retail Pharmacies
    • 10.3.3. Online Pharmacies
  • 10.4. Market Attractiveness Analysis By Distribution Channel

11. Global Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032, By Region

  • 11.1. Introduction / Key Findings
  • 11.2. Historical Market Size (US$ Bn) Analysis By Region, 2019-2023
  • 11.3. Current and Future Market Size (US$ Bn) Analysis and Forecast By Region, 2024-2032
    • 11.3.1. North America
    • 11.3.2. Latin America
    • 11.3.3. Europe
    • 11.3.4. East Asia
    • 11.3.5. South Asia
    • 11.3.6. Oceania
    • 11.3.7. Middle East and Africa
  • 11.4. Market Attractiveness Analysis By Region

12. North America Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

  • 12.1. Introduction
  • 12.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 12.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
    • 12.3.1. By Country
      • 12.3.1.1. U.S.
      • 12.3.1.2. Canada
    • 12.3.2. By Drug
    • 12.3.3. By Route of Administration
    • 12.3.4. By Distribution Channel
  • 12.4. Market Attractiveness Analysis
    • 12.4.1. By Country
    • 12.4.2. By Drug
    • 12.4.3. By Route of Administration
    • 12.4.4. By Distribution Channel
  • 12.5. Market Trends
  • 12.6. Key Market Participants - Intensity Mapping
  • 12.7. Drivers and Restraints - Impact Analysis
  • 12.8. Country Level Analysis & Forecast
    • 12.8.1. U.S. Vaginal Antifungals Market Analysis
      • 12.8.1.1. Introduction
      • 12.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 12.8.1.2.1. By Drug
        • 12.8.1.2.2. By Route of Administration
        • 12.8.1.2.3. By Distribution Channel
    • 12.8.2. Canada Vaginal Antifungals Market Analysis
      • 12.8.2.1. Introduction
      • 12.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 12.8.2.2.1. By Drug
        • 12.8.2.2.2. By Route of Administration
        • 12.8.2.2.3. By Distribution Channel

13. Latin America Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

  • 13.1. Introduction
  • 13.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 13.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
    • 13.3.1. By Country
      • 13.3.1.1. Mexico
      • 13.3.1.2. Brazil
      • 13.3.1.3. Argentina
      • 13.3.1.4. Rest of Latin America
        • 13.3.1.4.1. By Country
        • 13.3.1.4.2. By Drug
        • 13.3.1.4.3. By Route of Administration
        • 13.3.1.4.4. By Distribution Channel
  • 13.4. Market Attractiveness Analysis
    • 13.4.1. By Country
    • 13.4.2. By Drug
    • 13.4.3. By Route of Administration
    • 13.4.4. By Distribution Channel
  • 13.5. Market Trends
  • 13.6. Key Market Participants - Intensity Mapping
  • 13.7. Drivers and Restraints - Impact Analysis
  • 13.8. Country Level Analysis & Forecast
    • 13.8.1. Mexico Vaginal Antifungals Market Analysis
      • 13.8.1.1. Introduction
      • 13.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 13.8.1.2.1. By Drug
        • 13.8.1.2.2. By Route of Administration
        • 13.8.1.2.3. By Distribution Channel
    • 13.8.2. Brazil Vaginal Antifungals Market Analysis
      • 13.8.2.1. Introduction
      • 13.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 13.8.2.2.1. By Country
        • 13.8.2.2.2. By Drug
        • 13.8.2.2.3. By Route of Administration
        • 13.8.2.2.4. By Distribution Channel
    • 13.8.3. Argentina Vaginal Antifungals Market Analysis
      • 13.8.3.1. Introduction
      • 13.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 13.8.3.2.1. By Drug
        • 13.8.3.2.2. By Route of Administration
        • 13.8.3.2.3. By Distribution Channel

14. Europe Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

  • 14.1. Introduction
  • 14.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 14.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
    • 14.3.1. By Country
      • 14.3.1.1. Germany
      • 14.3.1.2. Italy
      • 14.3.1.3. France
      • 14.3.1.4. U.K.
      • 14.3.1.5. Spain
      • 14.3.1.6. BENELUX
      • 14.3.1.7. Russia
      • 14.3.1.8. Rest of Europe
    • 14.3.2. By Drug
    • 14.3.3. By Route of Administration
    • 14.3.4. By Distribution Channel
  • 14.4. Market Attractiveness Analysis
    • 14.4.1. By Country
    • 14.4.2. By Drug
    • 14.4.3. By Route of Administration
    • 14.4.4. By Distribution Channel
  • 14.5. Market Trends
  • 14.6. Key Market Participants - Intensity Mapping
  • 14.7. Drivers and Restraints - Impact Analysis
  • 14.8. Country Level Analysis & Forecast
    • 14.8.1. Germany Vaginal Antifungals Market Analysis
      • 14.8.1.1. Introduction
      • 14.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.1.2.1. By Drug
        • 14.8.1.2.2. By Route of Administration
        • 14.8.1.2.3. By Distribution Channel
    • 14.8.2. Italy Vaginal Antifungals Market Analysis
      • 14.8.2.1. Introduction
      • 14.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.2.2.1. By Drug
        • 14.8.2.2.2. By Route of Administration
        • 14.8.2.2.3. By Distribution Channel
    • 14.8.3. France Vaginal Antifungals Market Analysis
      • 14.8.3.1. Introduction
      • 14.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.3.2.1. By Drug
        • 14.8.3.2.2. By Route of Administration
        • 14.8.3.2.3. By Distribution Channel
    • 14.8.4. U.K. Vaginal Antifungals Market Analysis
      • 14.8.4.1. Introduction
      • 14.8.4.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.4.2.1. By Drug
        • 14.8.4.2.2. By Route of Administration
        • 14.8.4.2.3. By Distribution Channel
    • 14.8.5. Spain Vaginal Antifungals Market Analysis
      • 14.8.5.1. Introduction
      • 14.8.5.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.5.2.1. By Drug
        • 14.8.5.2.2. By Route of Administration
        • 14.8.5.2.3. By Distribution Channel
    • 14.8.6. BENELUX Vaginal Antifungals Market Analysis
      • 14.8.6.1. Introduction
      • 14.8.6.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.6.2.1. By Drug
        • 14.8.6.2.2. By Route of Administration
        • 14.8.6.2.3. By Distribution Channel
    • 14.8.7. Russia Vaginal Antifungals Market Analysis
      • 14.8.7.1. Introduction
      • 14.8.7.2. Market Analysis and Forecast By Market Taxonomy
        • 14.8.7.2.1. By Drug
        • 14.8.7.2.2. By Route of Administration
        • 14.8.7.2.3. By Distribution Channel

15. East Asia Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

  • 15.1. Introduction
  • 15.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 15.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
    • 15.3.1. By Country
      • 15.3.1.1. China
      • 15.3.1.2. Japan
      • 15.3.1.3. South Korea
    • 15.3.2. By Drug
    • 15.3.3. By Route of Administration
    • 15.3.4. By Distribution Channel
  • 15.4. Market Attractiveness Analysis
    • 15.4.1. By Country
    • 15.4.2. By Drug
    • 15.4.3. By Route of Administration
    • 15.4.4. By Distribution Channel
  • 15.5. Market Trends
  • 15.6. Key Market Participants - Intensity Mapping
  • 15.7. Drivers and Restraints - Impact Analysis
  • 15.8. Country Level Analysis & Forecast
    • 15.8.1. China Vaginal Antifungals Market Analysis
      • 15.8.1.1. Introduction
      • 15.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 15.8.1.2.1. By Drug
        • 15.8.1.2.2. By Route of Administration
        • 15.8.1.2.3. By Distribution Channel
    • 15.8.2. Japan Vaginal Antifungals Market Analysis
      • 15.8.2.1. Introduction
      • 15.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 15.8.2.2.1. By Drug
        • 15.8.2.2.2. By Route of Administration
        • 15.8.2.2.3. By Distribution Channel
    • 15.8.3. South Korea Vaginal Antifungals Market Analysis
      • 15.8.3.1. Introduction
      • 15.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 15.8.3.2.1. By Drug
        • 15.8.3.2.2. By Route of Administration
        • 15.8.3.2.3. By Distribution Channel

16. South Asia Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

  • 16.1. Introduction
  • 16.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 16.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
    • 16.3.1. By Country
      • 16.3.1.1. India
      • 16.3.1.2. Indonesia
      • 16.3.1.3. Malaysia
      • 16.3.1.4. Thailand
      • 16.3.1.5. Rest of South Asia
    • 16.3.2. By Drug
    • 16.3.3. By Route of Administration
    • 16.3.4. By Distribution Channel
  • 16.4. Market Attractiveness Analysis
    • 16.4.1. By Country
    • 16.4.2. By Drug
    • 16.4.3. By Route of Administration
    • 16.4.4. By Distribution Channel
  • 16.5. Market Trends
  • 16.6. Key Market Participants - Intensity Mapping
  • 16.7. Drivers and Restraints - Impact Analysis
  • 16.8. Country Level Analysis & Forecast
    • 16.8.1. India Vaginal Antifungals Market Analysis
      • 16.8.1.1. Introduction
      • 16.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 16.8.1.2.1. By Drug
        • 16.8.1.2.2. By Route of Administration
        • 16.8.1.2.3. By Distribution Channel
    • 16.8.2. Indonesia Vaginal Antifungals Market Analysis
      • 16.8.2.1. Introduction
      • 16.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 16.8.2.2.1. By Drug
        • 16.8.2.2.2. By Route of Administration
        • 16.8.2.2.3. By Distribution Channel
    • 16.8.3. Malaysia Vaginal Antifungals Market Analysis
      • 16.8.3.1. Introduction
      • 16.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 16.8.3.2.1. By Drug
        • 16.8.3.2.2. By Route of Administration
        • 16.8.3.2.3. By Distribution Channel
    • 16.8.4. Thailand Vaginal Antifungals Market Analysis
      • 16.8.4.1. Introduction
      • 16.8.4.2. Market Analysis and Forecast By Market Taxonomy
        • 16.8.4.2.1. By Drug
        • 16.8.4.2.2. By Route of Administration
        • 16.8.4.2.3. By Distribution Channel

17. Oceania Vaginal Antifungals Market 2019-2023 and Forecast 2024-2032

  • 17.1. Introduction
  • 17.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 17.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
    • 17.3.1. By Country
      • 17.3.1.1. Australia
      • 17.3.1.2. New Zealand
    • 17.3.2. By Drug
    • 17.3.3. By Route of Administration
    • 17.3.4. By Distribution Channel
  • 17.4. Market Attractiveness Analysis
    • 17.4.1. By Country
    • 17.4.2. By Drug
    • 17.4.3. By Route of Administration
    • 17.4.4. By Distribution Channel
  • 17.5. Key Market Participants - Intensity Mapping
  • 17.6. Drivers and Restraints - Impact Analysis
  • 17.7. Country Level Analysis & Forecast
    • 17.7.1. Australia Vaginal Antifungals Market Analysis
      • 17.7.1.1. Introduction
      • 17.7.1.2. Market Analysis and Forecast By Market Taxonomy
        • 17.7.1.2.1. By Drug
        • 17.7.1.2.2. By Route of Administration
        • 17.7.1.2.3. By Distribution Channel
    • 17.7.2. New Zealand Vaginal Antifungals Market Analysis
      • 17.7.2.1. Introduction
      • 17.7.2.2. Market Analysis and Forecast By Market Taxonomy
        • 17.7.2.2.1. By Drug
        • 17.7.2.2.2. By Route of Administration
        • 17.7.2.2.3. By Distribution Channel

18. Middle East and Africa (MEA) Vaginal Antifungals Market Analysis 2019-2023 and Forecast 2024-2032

  • 18.1. Introduction
  • 18.2. Historical Market Size (US$ Bn) Trend Analysis By Market Taxonomy, 2019-2023
  • 18.3. Current and Future Market Size (US$ Bn) Analysis & Forecast By Market Taxonomy, 2024-2032
    • 18.3.1. By Country
      • 18.3.1.1. GCC Countries
      • 18.3.1.2. Turkey
      • 18.3.1.3. South Africa
      • 18.3.1.4. North Africa
      • 18.3.1.5. Rest of Middle East and Africa
    • 18.3.2. By Drug
    • 18.3.3. By Route of Administration
    • 18.3.4. By Distribution Channel
  • 18.4. Market Attractiveness Analysis
    • 18.4.1. By Country
    • 18.4.2. By Drug
    • 18.4.3. By Route of Administration
    • 18.4.4. By Distribution Channel
  • 18.5. Market Trends
  • 18.6. Key Market Participants - Intensity Mapping
  • 18.7. Drivers and Restraints - Impact Analysis
  • 18.8. Country Level Analysis & Forecast
    • 18.8.1. GCC Countries Vaginal Antifungals Market Analysis
      • 18.8.1.1. Introduction
      • 18.8.1.2. Market Analysis and Forecast By Market Taxonomy
        • 18.8.1.2.1. By Drug
        • 18.8.1.2.2. By Route of Administration
        • 18.8.1.2.3. By Distribution Channel
    • 18.8.2. Turkey Vaginal Antifungals Market Analysis
      • 18.8.2.1. Introduction
      • 18.8.2.2. Market Analysis and Forecast By Market Taxonomy
        • 18.8.2.2.1. By Drug
        • 18.8.2.2.2. By Route of Administration
        • 18.8.2.2.3. By Distribution Channel
    • 18.8.3. South Africa Vaginal Antifungals Market Analysis
      • 18.8.3.1. Introduction
      • 18.8.3.2. Market Analysis and Forecast By Market Taxonomy
        • 18.8.3.2.1. By Drug
        • 18.8.3.2.2. By Route of Administration
        • 18.8.3.2.3. By Distribution Channel
    • 18.8.4. North Africa Vaginal Antifungals Market Analysis
      • 18.8.4.1. Introduction
      • 18.8.4.2. Market Analysis and Forecast By Market Taxonomy
        • 18.8.4.2.1. By Drug
        • 18.8.4.2.2. By Route of Administration
        • 18.8.4.2.3. By Distribution Channel

19. Market Structure Analysis

  • 19.1. Market Analysis By Tier of Companies
  • 19.2. Market Concentration
  • 19.3. Market Share Analysis of Top Players
  • 19.4. Market Presence Analysis

20. Competition Analysis

  • 20.1. Competition Dashboard
  • 20.2. Competition Benchmarking
  • 20.3. Competition Deep Dive
    • 20.3.1. Pfizer Inc.
      • 20.3.1.1. Overview
      • 20.3.1.2. Product Portfolio
      • 20.3.1.3. Sales Footprint
      • 20.3.1.4. Key Financials
      • 20.3.1.5. SWOT Analysis
      • 20.3.1.6. Strategic Overview
    • 20.3.2. Bausch Health Companies Inc
      • 20.3.2.1. Overview
      • 20.3.2.2. Product Portfolio
      • 20.3.2.3. Sales Footprint
      • 20.3.2.4. Key Financials
      • 20.3.2.5. SWOT Analysis
      • 20.3.2.6. Strategic Overview
    • 20.3.3. ANI Pharmaceuticals, Inc.
      • 20.3.3.1. Overview
      • 20.3.3.2. Product Portfolio
      • 20.3.3.3. Sales Footprint
      • 20.3.3.4. Key Financials
      • 20.3.3.5. SWOT Analysis
      • 20.3.3.6. Strategic Overview
    • 20.3.4. Hikma Pharmaceuticals Plc
      • 20.3.4.1. Overview
      • 20.3.4.2. Product Portfolio
      • 20.3.4.3. Sales Footprint
      • 20.3.4.4. Key Financials
      • 20.3.4.5. SWOT Analysis
      • 20.3.4.6. Strategic Overview
    • 20.3.5. Lupin Limited
      • 20.3.5.1. Overview
      • 20.3.5.2. Product Portfolio
      • 20.3.5.3. Sales Footprint
      • 20.3.5.4. Key Financials
      • 20.3.5.5. SWOT Analysis
      • 20.3.5.6. Strategic Overview
    • 20.3.6. Mycovia Pharmaceuticals, Inc.
      • 20.3.6.1. Overview
      • 20.3.6.2. Product Portfolio
      • 20.3.6.3. Sales Footprint
      • 20.3.6.4. Key Financials
      • 20.3.6.5. SWOT Analysis
      • 20.3.6.6. Strategic Overview
    • 20.3.7. Glenmark Pharmaceuticals Limited
      • 20.3.7.1. Overview
      • 20.3.7.2. Product Portfolio
      • 20.3.7.3. Sales Footprint
      • 20.3.7.4. Key Financials
      • 20.3.7.5. SWOT Analysis
      • 20.3.7.6. Strategic Overview
    • 20.3.8. Unique Pharmaceuticals
      • 20.3.8.1. Overview
      • 20.3.8.2. Product Portfolio
      • 20.3.8.3. Sales Footprint
      • 20.3.8.4. Key Financials
      • 20.3.8.5. SWOT Analysis
      • 20.3.8.6. Strategic Overview
    • 20.3.9. PEPTONIC medical AB
      • 20.3.9.1. Overview
      • 20.3.9.2. Product Portfolio
      • 20.3.9.3. Sales Footprint
      • 20.3.9.4. Key Financials
      • 20.3.9.5. SWOT Analysis
      • 20.3.9.6. Strategic Overview
    • 20.3.10. Aurobindo Pharma Limited
      • 20.3.10.1. Overview
      • 20.3.10.2. Product Portfolio
      • 20.3.10.3. Sales Footprint
      • 20.3.10.4. Key Financials
      • 20.3.10.5. SWOT Analysis
      • 20.3.10.6. Strategic Overview
    • 20.3.11. Dr. Reddy's Laboratories
      • 20.3.11.1. Overview
      • 20.3.11.2. Product Portfolio
      • 20.3.11.3. Sales Footprint
      • 20.3.11.4. Key Financials
      • 20.3.11.5. SWOT Analysis
      • 20.3.11.6. Strategic Overview
    • 20.3.12. SCYNEXIS, Inc.
      • 20.3.12.1. Overview
      • 20.3.12.2. Product Portfolio
      • 20.3.12.3. Sales Footprint
      • 20.3.12.4. Key Financials
      • 20.3.12.5. SWOT Analysis
      • 20.3.12.6. Strategic Overview
    • 20.3.13. Basilea Pharmaceutica Ltd.
      • 20.3.13.1. Overview
      • 20.3.13.2. Product Portfolio
      • 20.3.13.3. Sales Footprint
      • 20.3.13.4. Key Financials
      • 20.3.13.5. SWOT Analysis
      • 20.3.13.6. Strategic Overview
    • 20.3.14. Astellas Pharma Inc.
      • 20.3.14.1. Overview
      • 20.3.14.2. Product Portfolio
      • 20.3.14.3. Sales Footprint
      • 20.3.14.4. Key Financials
      • 20.3.14.5. SWOT Analysis
      • 20.3.14.6. Strategic Overview
    • 20.3.15. Grupo Ferrer Internacional, S.A.
      • 20.3.15.1. Overview
      • 20.3.15.2. Product Portfolio
      • 20.3.15.3. Sales Footprint
      • 20.3.15.4. Key Financials
      • 20.3.15.5. SWOT Analysis
      • 20.3.15.6. Strategic Overview
    • 20.3.16. Pacgen Life Science Corporation
      • 20.3.16.1. Overview
      • 20.3.16.2. Product Portfolio
      • 20.3.16.3. Sales Footprint
      • 20.3.16.4. Key Financials
      • 20.3.16.5. SWOT Analysis
      • 20.3.16.6. Strategic Overview
    • 20.3.17. NovaDigm Therapeutics, Inc.
      • 20.3.17.1. Overview
      • 20.3.17.2. Product Portfolio
      • 20.3.17.3. Sales Footprint
      • 20.3.17.4. Key Financials
      • 20.3.17.5. SWOT Analysis
      • 20.3.17.6. Strategic Overview
    • 20.3.18. Cidara Therapeutics, Inc.
      • 20.3.18.1. Overview
      • 20.3.18.2. Product Portfolio
      • 20.3.18.3. Sales Footprint
      • 20.3.18.4. Key Financials
      • 20.3.18.5. SWOT Analysis
      • 20.3.18.6. Strategic Overview
    • 20.3.19. Amplyx Pharmaceuticals Inc.
      • 20.3.19.1. Overview
      • 20.3.19.2. Product Portfolio
      • 20.3.19.3. Sales Footprint
      • 20.3.19.4. Key Financials
      • 20.3.19.5. SWOT Analysis
      • 20.3.19.6. Strategic Overview

21. Assumptions and Acronyms Used

22. Research Methodology